BioCardia, Inc. Common Stock vs. Moderna, Inc. Common Stock
BioCardia, Inc. Common Stock and Moderna, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BCDA | MRNA | |
|---|---|---|
| Market Cap | $15.00 million | $69.62 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | — | $-3,151,000,000 |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| BCDA | MRNA | |
|---|---|---|
| Price / Book | — | 10.30 |
| Price / Sales | — | 31.25 |
BCDA and MRNA split the valuation factors evenly.
Profitability
| BCDA | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | — | -46.61% |
BCDA and MRNA split the profitability factors evenly.
Risk & Sentiment
| BCDA | MRNA | |
|---|---|---|
| Short Interest | 0.00% | 0.01% |
BCDA leads on 1 of 1 risk & sentiment factors.
Dig deeper: BCDA overview, BCDA financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.